United States
Germany
Japan
United Kingdom
China
EPHX2 (NM_001979) Human Tagged ORF Clone Lentiviral Particle
CAT＃: RC202489L2V
- LentiORF®
-
Lenti ORF particles, EPHX2 (mGFP-tagged) - Human epoxide hydrolase 2, cytoplasmic (EPHX2), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 9,975.00
货期*
详询
规格
Product images
经常一起买 (3)
EPHX2 mouse monoclonal antibody, clone OTI1A6 (formerly 1A6)
CNY 1,999.00
CNY 2,700.00
Specifications
| Product Data | |
| Product Name | EPHX2 (NM_001979) Human Tagged ORF Clone Lentiviral Particle |
| Synonyms | ABHD20; CEH; SEH |
| Vector | pLenti-C-mGFP |
| ACCN | NM_001979 |
| ORF Size | 1665 bp |
| Sequence Data |
The ORF insert of this clone is exactly the same as(RC202489).
|
| OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| Reference Data | |
| RefSeq | NM_001979.4 |
| RefSeq Size | 2290 bp |
| RefSeq ORF | 1668 bp |
| Locus ID | 2053 |
| Domains | abhydrolase, Hydrolase |
| Protein Pathways | Arachidonic acid metabolism, Metabolic pathways |
| MW | 62.6 kDa |
| Gene Summary | This gene encodes a member of the epoxide hydrolase family. The protein, found in both the cytosol and peroxisomes, binds to specific epoxides and converts them to the corresponding dihydrodiols. Mutations in this gene have been associated with familial hypercholesterolemia. Alternatively spliced transcript variants have been described. [provided by RefSeq, Feb 2012] |
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
You may also need
Customer
Reviews
Loading...
